Costica Aloman, M.D., joined Westchester Medical Center in January 2024. He is board certified in Internal Medicine, Gastroenterology, and Transplant Hepatology. Dr. Aloman cares for patients with complex and advanced liver diseases, with special focus on patients with end stage liver disease requiring liver transplant as well as post-liver transplant care. He believes in the value of personalized management of liver diseases using the latest up to date approaches and in the importance of practicing wisely and compassionately.

He has extensive experience in managing patients with complex liver cases acquired during his clinical activities at Mount Sinai Medical Center in New York, University of Illinois at Chicago, and Rush University Medical Center in Chicago. He has been listed in Chicago Magazine 2020-2024 on the Top Doctors list. Dr. Aloman is actively involved in basic research of dendritic cell biology, liver fibrosis, mechanisms responsible for autoimmunity, and liver cancer. He has very active in clinical research and has been site principal investigator for clinical trials exploring new treatments for viral hepatitis, alcohol associated liver disease, and liver cirrhosis.

Education

• Fellowship: Mount Sinai Hospital, Transplant Hepatology and Rhode Island Hospital (Providence), Gastroenterology
• Residency: University of Iowa Hospitals and Clincs, Internal Medicine and Fundeni Clinical Hospital, Gastroenterology 
• M.D., University of Illinois College of Medicine 
• Ph.D., Carol Davila University of Medicine and Pharmacy

Areas of Expertise

• Liver transplant evaluation
• End stage liver disease
• Post-liver transplant care
• Autoimmune hepatitis
• Alcohol associated liver disease

Publications

• Shiffman M, Da B, Goel A, et. al. "Larsucosterol for the Treatment of Alcohol-Associated Hepatitis." NEJM evidence, 4(2), (2025) EVIDoa2400243. doi: 10.1056/EVIDoa2400243
• Belilos E, Strzepka J, Ritz E, et. al. "Characterizing outcomes in a large cohort of latinx patients with autoimmune hepatitis." Annals of hepatology, 30(1), (2024) 101570. doi: 10.1016/j.aohep.2024.101570
• Doyle EH, Aloman C, El-Shamy A, et. al. "Imprinted immune abnormalities in liver transplant patients cured of hepatitis C with antiviral drugs." Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 30(7), (2024) 728-741. doi: 10.1097/LVT.0000000000000342
• Ma N, Yip R, Lewis S, et. al. "Environmental exposures are important risk factors for advanced liver fibrosis in African American adults." JHEP reports : innovation in hepatology, 5(4), (2023) 100696. doi: 10.1016/j.jhepr.2023.100696
• Strzepka J, Schwartz BA, Ritz EM, et. al. "Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes." Journal of clinical gastroenterology, 58(1), (2024) 91-97. doi: 10.1097/MCG.0000000000001817
• Kim M, Hui KM, Shi M, et. al. "Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma." Hepatology communications, 6(11), (2022) 3247-3259. doi: 10.1002/hep4.2079
• Efe C, Lammert C, Taşçılar K, et. al. "Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis." Liver international : official journal of the International Association for the Study of the Liver, 42(3), (2022) 607-614. doi: 10.1111/liv.15121

View All Publications

Memberships and Affiliations

• American Association for the Study of Liver Diseases
• American Gastroenterological Association

Teaching Responsibilities

• Hepatology Teaching Attending-Gastroenterology
• Hepatology Fellowship Program